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Abstract
Despite effective antibiotic therapy, about one-third of patients
admitted to an intensive care unit (ICU) with severe community-
acquired pneumonia (CAP) and organ dysfunction die within a
month. This high death rate demonstrates the need for additional
interventions. Both animal models and clinical data suggest that
pathological expression of tissue factor (TF), with consequent
activation of coagulation and inflammatory processes, contributes
to the morbidity and mortality associated with CAP. TF pathway
inhibitor (TFPI) is an endogenous molecule with both anti-
inflammatory and anti-coagulant activity. In severe CAP, endoge-
nous TFPI is overwhelmed by increased expression of TF. In this
setting administration of recombinant TFPI (tifacogin) could restore
hemostasis. The OPTIMIST Phase 3 trial of tifacogin in severe
sepsis did not show overall mortality benefit from tifacogin. How-
ever, retrospective analysis suggested improved survival among
tifacogin treated patients who had severe CAP. Benefit seemed
clearest when such patients had not received concurrent heparin
and/or when they had documented microbial infection. These
findings led to a prospective study (CAPTIVATE) in which 2,100
patients with severe CAP requiring ICU admission were
randomized to standard care plus either placebo or one of two
dose levels of tifacogin. The study excluded concomitant heparin
and encouraged documentation of infection. Enrolment was
completed in July 2008 but data are not yet available. The primary
outcome measure is 28-day all-cause mortality. In addition to short-
term and long-term survival, the study is collecting data on adverse
events (particularly when related to bleeding or thrombosis) and
the effect of tifacogin on disease progression, resource use, and
duration of ICU and hospital stay.
Introduction
As with injury to the blood vessel wall, certain systemic
disease states (notably severe infection and sepsis) result in
expression of tissue factor (TF) on vascular cells. Contact of
TF with blood leads to binding between TF and factor VII
[1,2]. The activated TF-activated factor VIIa (FVIIa) complex
converts factor X to activated factor X, and triggers both
thrombin formation and proinflammatory intracellular signal-
ing, in which protease-activated receptor (PAR)-1 and PAR-2
are involved. It is likely that over-expression of TF, both
systemically and in the lung, contributes to the patho-
physiology of severe community-acquired pneumonia (CAP)
[3,4], which is associated with a 28-day all-cause mortality in
excess of 30% [5,6].
TF pathway inhibitor (TFPI) is an endogenous molecule with
both anti-inflammatory and anti-coagulant activities (Figure 1).
However, in severe infection endogenous TFPI is over-
whelmed by increased expression of TF [7]. Data from both
animal models and from the clinic suggest that, in this setting,
administration of recombinant TFPI (tifacogin) can reduce
acute lung injury and improve prospects for survival.
From laboratory to clinic
In a baboon model of potentially lethal septic shock induced
by intravenous infusion of Escherichia coli, administration of
recombinant TFPI 6 mg/kg significantly attenuated the coagu-
lation response, decreased damage to target organs, inclu-
ding the lung, and reduced mortality [8]. In a rat model of lung
injury induced by lipopolysaccharide (LPS), treatment with
recombinant TFPI before and after the insult reduced vascular
permeability, edema, neutrophil infiltration, and production of
tumor necrosis factor-α by stimulated monocytes [9].
The role played by the TF-FVIIa complex in acute lung injury
has been confirmed by work conducted in an E. coli baboon
model, which showed that both TFPI and site-inactivated
FVIIa (a competitive inhibitor of TF) have protective effects
[4]. Site-inactivated FVIIa has also been shown to reduce
local release of proinflammatory cytokines, preserve gas
exchange, and reduce fibrin deposition and lung edema
following intratracheal administration of LPS in rats [10]. It
Review
Beyond antibiotics in severe community-acquired pneumonia:
the role and rationale for tissue factor pathway inhibition
Pierre-Francois Laterre
St Luc University Hospital, Université Catholique de Louvain, UCL, 1200 Brussels, Belgium
Corresponding author: Pierre-Francois Laterre, Pierre-Francois.Laterre@uclouvain.be
Published: 26 November 2008 Critical Care 2008, 12(Suppl 6):S4 (doi:10.1186/cc7027)
This article is online at http://ccforum.com/content/12/S6/S4
© 2008 BioMed Central Ltd
CNS = central nervous system; FVIIa = activated factor VII; ICU = intensive care unit; IL = interleukin; INR = international normalized ratio; LPS =
lipopolysaccharide; OPTIMIST = Optimized Phase 3 Tifacogin in Multicenter International Sepsis Trial; PAR = protease-activated receptor; PF =
prothrombin fragment; TF = tissue factor; TFPI = tissue factor pathway inhibitor.Page 2 of 6
(page number not for citation purposes)
Critical Care    Vol 12 Suppl 6 Laterre
has been established that TFPI is able to attach the LPS-
binding protein complex [11], altering the host response to
bacteria through interaction with Toll-like receptors and
CD14.
These laboratory findings formed the rationale for the initial
investigation of recombinant TFPI in the clinic. In 2001, a
randomized, controlled Phase 2 trial conducted in 210
patients with severe sepsis provided evidence of a survival
benefit [12]. Mortality among patients given tifacogin (at
doses of 0.025 or 0.05 mg/kg per hour infused over 96 hours)
was 30%. This was appreciably lower than the 38% rate of
mortality seen among patients in the placebo group (not
significant). Logistic regression analysis suggested that
greater activation of coagulation at baseline, indicated by a
higher international normalized ratio (INR), was associated
with a more pronounced benefit from tifacogin. Evidence of
biological activity of tifacogin was demonstrated by reduced
formation of thrombin and thrombin-antithrombin complex,
and lower levels of the inflammatory mediator IL-6. No excess
of bleeding events was observed in the tifacogin-treated
group. These encouraging findings led to the design of the
initial Phase 3 trial, described below.
Study TFP007: OPTIMIST
The Phase 3 trial OPTIMIST (Optimized Phase 3 Tifacogin in
Multicenter International Sepsis Trial) [13] included 1,754
patients, who were randomly assigned to either placebo or
tifacogin, given as an infusion of 0.025 mg/kg per hour over a
period of 96 hours. Patients included had at least two
dysfunctional organs and an INR of 1.2 or greater. The two
groups were well matched in terms of mean age (62 years in
both groups), baseline Acute Physiology and Chronic Health
Evaluation (APACHE) II score (25 in both groups), and organ
dysfunction (3.1 in the placebo group, 3.0 among tifacogin-
treated patients). The two arms of the study were also closely
matched in terms of other relevant variables. The overall 28-
day mortality rates in the tifacogin and placebo groups were
34.2% and 33.9% (P = 0.75), respectively, after adjustment
per protocol for baseline APACHE II score and IL-6.
A second, smaller group of 201 patients with a less severe
coagulation abnormality was subsequently enrolled as a
safety cohort. Among patients in this secondary cohort, who
all had an INR of less than 1.2, the 28-day mortality rate
among those who received tifacogin was significantly lower
than that in the placebo group (12.0% versus 22.9%;
P = 0.025). Although overall the trial was unable to identify a
survival benefit for tifacogin, this finding suggested that
tifacogin might have greater efficacy among subgroups of
patients. It was also hypothesized that the explanation for the
negative results might lie in the fact that heparin prophylaxis
for deep vein thrombosis had been permitted in the main
study [13].
Efficacy in subgroups defined by heparin exposure and
documentation of infection by culture
There is a biological interaction between TFPI and heparin
[14]. TFPI exhibits competitive low-affinity binding with glyco-
soaminoglycans, and heparin causes release of endogenous
TFPI from its binding sites on endothelium. The majority of
patients in the study received heparin prophylaxis during or
after study drug infusion (either unfractionated heparin or low-
molecular-weight heparin). Heparin prophylaxis was left to the
discretion of the clinician, and randomization was not
stratified according to heparin use.
In these patients there may have been inadequate interaction
between tifacogin and the TF/FVIIa complex, resulting in
reduced efficacy of TFPI. Subgroup analyses were therefore
undertaken to distinguish between patients who had received
any dose of heparin, with the exception of heparin flushes for
arterial lines, and those who had not. Because the type of
heparin used was highly variable at each investigator site, no
analysis was performed to correlate heparin dose with clinical
or biological responses. Analyses were conducted separately
for patients with levels of circulating prothrombin fragment
(PF)1.2 of 3 ng/ml or greater (which reflects pronounced
activation of coagulation) and those with PF1.2 levels of less
than 3 ng/ml. Among the 238 patients with greater activation
Figure 1
TFPI anti-coagulant and anti-inflammatory activities. TFPI limits the
conversion by the TF-FVIIa complex from factor X to Xa and thrombin
formation, and thereby reduces proinflammatory intracellular signaling
via PAR-1 and PAR-2 receptors. TFPI attaches the LPS-binding
protein complex and alters the host responses to bacteria through
interaction with TLRs and CD14. hegr-1, human early growth response
protein-1; hGADD45, growth arrest and DNA damage inducible gene;
hIL-6, human interleukin-6; hIL-8, human interleukin-8; hJunB,
oncogene; hNOS, human nitric oxide synthase; JNK, Jun amino-
terminal kinase; LPS, lipopolysaccharide; lyn, oncogene homolog, Src;
MAPK, mitogen-activated protein kinases; PAK, p21-activated protein
kinase; PAR, protease-activated receptor; Pl3K, phosphatidylinositol-3-
kinase; PKC, protein kinase C; PLCb, phospholipase Cβ; SAPK,
stress-activated protein kinase; Smad, moderates activity of TGF-β
ligands; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TLR,
Toll-like receptor; Yes, a tyrosine protein kinase.Page 3 of 6
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of coagulation who did not receive heparin, there was
evidence of a significant benefit from tifacogin. Mortality in the
placebo group was approximately 50%, whereas that in the
tifacogin-treated group was approximately 30% (P = 0.007;
Figure 2). No such effect was observed among patients not
receiving heparin patients who exhibited less pronounced
activation of coagulation, and neither was this effect
observed among patients who had received heparin.
Many patients enrolled in sepsis trials have suspected infec-
tion that is not subsequently documented. If at least part of
the mechanism of action of tifacogin is through modulation of
the host’s antibacterial response, then the presence of
infection may influence the efficacy of tifacogin.
Aspects of inflammatory signaling relate to innate mecha-
nisms of immunity. TFPI is known to have relevant effects
such as LPS binding and inhibition of the interaction of the
LPS/LPS-binding protein complex with CD-14 and Toll-like
receptor-4 [11].
Investigators therefore examined outcome by culture status.
Independent of heparin exposure, patients in the primary
cohort (INR ≥1.2) who had infection documented by positive
blood culture exhibited a strong trend toward reduced
mortality when they were given tifacogin rather than placebo
(mortality rate 27.7% versus 35.4%; P = 0.054). There was
no sign of survival benefit among patients with positive
evidence of infection other than blood culture. Also, among
patients who had a negative culture or whose infection status
was not determined, there was evidence that the tifacogin
group fared worse (mortality rate 40.1% versus 30.0% in the
placebo group; P = 0.02; Table 1).
The suggestion of mortality benefit among patients with
positive blood culture was stronger still when only those
patients not exposed to heparin were included in the
subgroup analysis. In this instance, the mortality among
placebo patients was 40.0% but only 26.9% among those
who received tifacogin (P = 0.05; Table 2).
Bleeding or thrombotic events
Overall, the incidence of bleeding events (during infusion or
within 2 days) was similar in the tifacogin and placebo groups
(4% versus 3%). The risk for any thromboembolic event over
the 28 day study period was identical (at 3%) in the two arms
of the study. This rate of 3% was the same in patients
exposed to tifacogin alone and in patients who had also been
treated with heparin. This finding does not imply that heparin
prophylaxis is not mandatory in critically ill patients, but it
provides certain reassurance that the current randomized trial
of tifacogin versus placebo (see the section on CAPTIVATE,
below) is justified. Indeed, patients who were not receiving
heparin in the OPTIMIST trial had more pronounced coagula-
tion disturbances and lower platelet count, and were therefore
less likely to require prophylaxis against deep vein thrombosis.
No placebo patient experienced a central nervous system
(CNS) bleed. This compares with five cases among tifacogin
Available online http://ccforum.com/content/12/S6/S4
Figure 2
28-Day mortality: heparin versus no heparin. Shown are 28-day
all-cause mortality rates in patients with or without heparin prophylaxis
during the 4-day study drug infusion according to prothrombin
fragment (PF)1.2 plasma levels. TFPI, tissue factor pathway inhibitor.
Table 1
28-Day all-cause mortality in TFPI-treated and placebo-treated
patients
Overall
INR ≥1.2 Placebo TFPI P
Positive blood culture
n 257 278
Total (%) 29.4 31.6 0.054
Mortality (%) 35.4 27.7
Positive other
n 387 370
Total (%) 44.3 42.0 0.94
Mortality (%) 35.1 35.4
Negative culture/not done
n 230 232
Total (%) 26.3 26.4 0.02
Mortality (%) 30.0 40.1
Presented are 28-day all-cause mortality rates in TFPI and placebo-
treated patients with positive blood cultures, other documented
infections, and negative culture or undocumented infections. INR,
international normalized ratio; TFPI, Tissue factor pathway inhibitor.patients, but this represents an incidence of less than 1%.
Moreover, the increased risk for a hemorrhagic CNS event
was counterbalanced by a decreased risk for an ischaemic
CNS event. These were experienced by eight patients in the
placebo group and by one patient with tifacogin.
Defining a patient group for further study
In a further attempt to elucidate the potential benefit of
tifacogin in critically ill patients, the OPTIMIST study’s clinical
evaluation committee reviewed the information provided
initially by participating centers and extracted findings only for
those 496 patients who were judged to have had severe
CAP. In these severe CAP patients overall, there was a trend
toward improved survival in those who received tifacogin
rather than placebo (mortality rate 27.9% versus 32.7%;
P = 0.25). This finding, albeit not statistically significant, was
stronger when only those severe CAP patients with a
microbiologically identified infection were included in the
analysis. In this setting mortality with tifacogin was 27.1%, as
compared with 35.7% with placebo (P = 0.09).
A suggestion of benefit was also seen when only patients
with severe CAP who did not receive heparin were included
in the analysis; mortality with tifacogin was 29.1%, as
compared with 42.3% in the placebo group (P = 0.08). The
effect became statistically significant when analysis was
confined to patients with severe CAP with an identified
infectious organism and no concomitant heparin exposure. In
this group (n = 86), the 51.9% mortality rate among placebo
patients was significantly higher than the 29.3% rate seen
among tifacogin-treated patients (P = 0.02).
Among patients with severe CAP, a post hoc analysis of data
from the OPTIMIST trial performed by a blinded clinical
evaluation committee identified a trend toward benefit from
tifacogin among patients in shock but not in those without
shock [15]. The same pattern was seen for requirement for
ventilation. Interestingly, a trend toward lower 28-day all-
cause mortality in patients receiving tifacogin was present
across all quartiles of APACHE II score, suggesting a survival
benefit independent of baseline severity and not restricted to
severe CAP with multiple organ dysfunction.
These subgroup analyses were retrospective and, in some
cases, involved small numbers of patients, with the attendant
risk that prognostic variables were not well balanced across
groups. However, there is encouraging consistency in the
pattern that emerges. It appears that there is indeed potential
benefit from tifacogin, provided that patients are not exposed to
concomitant heparin, and there is a clear biological rationale to
explain why there could be a negative interaction between the
two agents. Furthermore, it appears that patients in whom a
tifacogin benefit is most likely are those with severe CAP with a
documented infection. These findings were influencing factors
in the design of the ongoing Phase 3 CAPTIVATE study.
CAPTIVATE (Community Acquired Pneumonia
Tifacogin Intra Venous Administration Trial
for Efficacy)
The objective of this large, multicentre, placebo-controlled
Phase 3 study (protocol number TFP561A2308) is to deter-
mine the safety and efficacy of tifacogin in adults with severe
CAP admitted to the intensive care unit (ICU). The target
accrual was 2,100 patients and enrollment was completed
in July 2008. No data are currently available, and none of the
investigator or steering committee members had access to
the data. The databank should be closed by December
2008.
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Table 2
28-Day all-cause mortality in patients with and those without heparin prophylaxis
Any heparin No heparin
INR ≥1.2 Placebo TFPI P Placebo TFPI P
Positive blood culture
n 162 174 0.31 95 104 0.05
Mortality (%) 32.7 28.2 40.0 26.9
Positive other
n 271 267 0.39 116 103 0.24
Mortality (%) 30.6 34.5 45.7 37.9
Negative culture/not done
n 167 159 0.01 63 73 0.98
Mortality (%) 25.7 39.6 41.3 41.1
Presented are 28-day all-cause mortality rates in patients with or without heparin prophylaxis during the study drug infusion period and with positive
blood cultures, other documented infections, and negative culture or undocumented infections. INR, international normalized ratio; TFPI, Tissue
factor pathway inhibitor.Eligible patients have a clinical diagnosis of CAP based on
the presence of at least two relevant signs (fever, tachypnea,
leukocytosis, or hypoxemia) and radiographic findings of new
pulmonary infiltrates within 24 hours of hospital admission. To
fulfill the condition for severity, patients must either meet both
the major Infectious Diseases Society of America/American
Thoracic Society criteria (shock or requirement for ventilation)
or have one major criterion or at least two minor ones.
Because of the low but clinically relevant risk for bleeding,
patients with a platelet count below 60,000/ml at baseline
are excluded from the study.
In an attempt to document infection as thoroughly as pos-
sible, sputum and blood samples are collected during screen-
ing of the patient, along with urine for antigen determination.
However, positive microbiology is not a requirement for study
entry. Even so, the rate of microbiological documentation for
patients accrued in Europe and Australia is running at 60%,
and the rate for the trial overall will probably reach 50%.
In addition to receiving standard therapy in the ICU, patients
are randomly assigned to one of three study arms: high-dose
tifacogin (0.075 mg/kg per hour), low-dose tifacogin
(0.025 mg/kg per hour), or matching placebo. Drug or
placebo is administered by continuous intravenous infusion
over 96 hours. Infusion must be commenced within 72 hours
of hospital admission and within 36 hours of entry to the ICU.
Prompt administration of tifacogin has been specified to
ensure intervention takes place relatively early in the course of
the disease process, before the development of disseminated
intravascular coagulation and multiple organ failure.
The trial excludes patients requiring heparin therapy (either
unfractionated or low-molecular-weight heparin), and use of
heparin prophylaxis is not permitted during tifacogin infusion.
During this 4-day period, thromboprevention is achieved with
the use of intermittent compression devices. After the 4-day
study drug infusion is completed, patients are allowed to
receive heparin prophylaxis. Investigators have been asked to
actively seek the development of any venous or arterial
thrombotic event during and after study drug administration.
To date, safety review by an external data monitoring com-
mittee has not identified any incidence of thromboembolic or
bleeding events. The ongoing study also excludes patients
receiving or expected to require treatment with drotrecogin
alfa (activated protein C).
The primary end-point of the trial is all-cause mortality at
28-days in the intent-to-treat population. Comparisons will be
made between patients randomly assigned to placebo, and
tifacogin 0.025 mg/kg and tifacogin 0.075 mg/kg. Analyses
of tifacogin efficacy in relation to culture documentation of
infection, baseline disease severity, and baseline coagulation
status have been prespecified. To evaluate longer term
outcome, data are being collected on survival at 90 days,
6 months, and 1 year.
To further contribute to our understanding of tifacogin’s
mechanism of action, the study is assessing changes in the
coagulation biomarkers D-dimer, PF1.2, and thrombin-anti-
thrombin complex. Pharmacoeconomic aspects of the trial
include measures of resource utilization, the need for mech-
anical ventilation, and the duration of ICU and hospital stay.
Discussion
The preclinical data reviewed by other contributors to this
supplement and the subgroup analyses of the initial Phase 3
OPTIMIST tifacogin trial described above provide a rationale
for use of tifacogin in patients with severe CAP and hence for
the ongoing CAPTIVATE study.
Subgroup analyses supporting the design of the CAPTIVATE
trial have serious limitations because they considered small
populations and therefore were statistically underpowered
and potentially overestimated the effects of the studied drug.
TFPI benefits in severe CAP have been retrospectively
observed in patients with documented infection and in the
absence of heparin prophylaxis. The outcome of the
CAPTIVATE study will indicate whether this is reflected in
improved outcomes in this large and important group of
patients, whose mortality has not fallen appreciably since the
1950s. Also, the absence of heparin prophylaxis against
deep vein thrombosis during the 4-day study drug infusion
period may raise concerns. If the incidence of thrombotic
events is increased in the placebo group compared with
TFPI, then this may suggest that the outcome benefit is driven
by the absence of heparin prophylaxis in this critically ill
population. However, mechanical compression devices used
in the study have been shown to be as effective as heparin
prophylaxis in preventing peripheral thrombotic complications
and should achieve adequate standard care.
The leading geographical region for enrollment has been
Europe, followed by North America and Australia/New Zealand.
Four unblinded safety evaluations have been conducted,
along with two interim analyses. The fact that the study has
been completed suggests that there have been no
appreciable safety concerns and that there are indications of
efficacy. The study has been successful in accruing its target
population; retrospective scrutiny by the clinical evaluation
committee has confirmed the CAP diagnosis in all but 6.5%
of cases. Forty-seven per cent of patients to date have
definite microbiological evidence of infection. Use of urine
antigen tests, especially in European ICUs, has contributed to
this encouragingly high level. This level of documented
infection exceeds that seen in any comparable study.
It is increasingly accepted that severe CAP is a condition in
which abnormal coagulation and an excessive host
inflammatory response play an important role. Based on this
understanding, a number of strategies for reducing morbidity
and mortality are being pursued. Among them is use of
glucocorticoid or other anti-inflammatory agents. At present,
Available online http://ccforum.com/content/12/S6/S4
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intervention are likely to outweigh the risk for adverse effects
cannot be identified. There appears to be a correlation
between persistent inflammation (evident based on raised
levels of IL-6, for example) and cardiovascular events occur-
ring even during the weeks and months after pneumonia. This
might justify further investigation into an anti-inflammatory
strategy. However, stringent efforts to reduce early mortality
through an intervention that has the potential to attenuate
both the coagulopathy and the inflammatory processes
associated with severe CAP continue to be a major priority.
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